These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Diagnosis and the current trends in multiple myeloma therapy. DmoszyĆska A Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817 [TBL] [Abstract][Full Text] [Related]
7. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Lacy MQ; Tefferi A Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients]. Mellstedt H; Gimsing P; Waage A Lakartidningen; 2011 Oct 19-25; 108(42):2090-4. PubMed ID: 22165535 [No Abstract] [Full Text] [Related]
9. Novel agents in the frontline management of multiple myeloma. Loong HH Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib for myeloma -- much ado about something. Dispenzieri A N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811 [No Abstract] [Full Text] [Related]
11. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756 [TBL] [Abstract][Full Text] [Related]
15. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide. Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555 [TBL] [Abstract][Full Text] [Related]
16. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209 [TBL] [Abstract][Full Text] [Related]
20. [It is not necessary to use novel agents to all patients with newly diagnosed myeloma as an initial therapy]. Takamatsu Y Rinsho Ketsueki; 2012 Jun; 53(6):587-93. PubMed ID: 22790633 [No Abstract] [Full Text] [Related] [Next] [New Search]